- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Medicis expands with purchase of LipoSonix
Scottsdale, Ariz. - Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
Scottsdale, Ariz.
- Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
The company is set to pay $300 million for LipoSonix, with $150 million to be paid up front to acquire the privately-owned company along with its 40 employees and research facilities. Medicis will pay the other $150 million after the U.S. approval process is complete and the technique reaches certain worldwide goals, according to the Tribune.
